|
|
|
|
|
by zozbot234
2108 days ago
|
|
> We already have tens of thousands of bright scientists who work on drugs where the patents go to the corporations, not for those who actually did the research anyway. That's because corporations do the part of drug research that actually matters, viz. translational research and safety/effectiveness studies. And it would be just as expensive if non-profits were doing it, so talking about "profits" is just not relevant. |
|
What probably would change is the choices on which conditions and drugs to target, and to what degree. Conceivably could shift from an ability-to-pay focus to an impact focus.
Exercise left to the reader to decide if that would be desirable and/or likely to be more successful overall.